Welcome, Guest. Please login or register.

Author Topic: Transdel Pharmaceuticals Submits to the FDA the Phase 3 Clinical Study of Ketotransdel(TM) for the Treatment of Acute Pain  (Read 1007 times)

0 Members and 1 Guest are viewing this topic.

The Web Team

  • Hero Member
  • *****
  • Posts: 8755
  • Karma: 14
    • View Profile
    • Qwoter
Transdel Pharmaceuticals Submits to the FDA the Phase 3 Clinical Study of Ketotransdel(TM) for the Treatment of Acute Pain
           


LA JOLLA, CA--(Marketwire - February 7, 2008) -  Transdel Pharmaceuticals, Inc. (OTCBB: TDLP),
a specialty pharmaceutical company focused on the development and
commercialization of non-invasive topically targeted medications, announced
today that it submitted its Phase 3 clinical study to the Food and Drug
Administration (FDA) for the Company's lead topical drug, KetotransdelT.
Ketotransdel is a novel, topical cream-based non-steroidal
anti-inflammatory drug (NSAID) for the treatment of acute pain. The Company
plans to initiate Phase 3 clinical trials following the FDA's 30-day review
period.

           

http://www.marketwire.com/mw/release.do?id=818583&sourceType=3
           
The Web Team
Qwoter.com

Tags:
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
925 Views
Last post February 05, 2008, 09:00:28 AM
by The Web Team
0 Replies
963 Views
Last post February 26, 2008, 09:00:55 AM
by The Web Team
0 Replies
1029 Views
Last post April 14, 2008, 06:00:35 AM
by The Web Team
0 Replies
1064 Views
Last post May 13, 2008, 10:52:15 AM
by The Web Team
0 Replies
1013 Views
Last post July 08, 2008, 03:08:38 PM
by The Web Team
0 Replies
1131 Views
Last post July 14, 2008, 03:10:46 PM
by The Web Team
0 Replies
1009 Views
Last post July 31, 2008, 06:12:07 AM
by The Web Team
0 Replies
1754 Views
Last post November 13, 2008, 09:00:21 AM
by The Web Team
0 Replies
600 Views
Last post May 12, 2009, 12:09:37 PM
by godoftrading
0 Replies
1655 Views
Last post June 05, 2012, 09:46:41 AM
by justo